Exparel 266 MG/20 ML vial 20ML
Ended Awarded Last action
- Contract number
- SPE2DR26FQHV0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,837
Award facts
- Contract value 100% obligated
- $12,836.60 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,836.60 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EXPAREL 266 mg/20 ml vials. This firm fixed-price delivery order was issued on January 23, 2026, with an ultimate completion date of February 13, 2026, and represents a non-set-aside procurement. The award was issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy that establishes multiple regional prime vendor contractors to supply diverse pharmaceutical products and medical consumables to Department of Defense healthcare facilities.
DMS Pharmaceutical Group serves as a critical supplier within the federal pharmaceutical supply chain, leveraging its small business designation to compete effectively in government procurement while maintaining consistent performance across multiple therapeutic categories. The company's comprehensive product portfolio includes branded and generic medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables such as EXPAREL—a local anesthetic used in surgical procedures. As a single-award prime vendor under the PPV-G GEN V contract (SPE2DR), which carries a $499,999,999 ceiling and extends through December 31, 2036, DMS Pharmaceutical Group is positioned to support recurring medical supply needs of military healthcare operations worldwide, with no subcontractors identified in this award documentation.
Quick answers
Who was awarded contract SPE2DR26FQHV0?
SPE2DR26FQHV0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 23, 2026.
How much is contract SPE2DR26FQHV0 worth?
The government has obligated $12,837 on SPE2DR26FQHV0.
Is contract SPE2DR26FQHV0 an order under another contract?
Yes. SPE2DR26FQHV0 is a delivery order under SPE2DR25D9759, an indefinite delivery contract.
Was contract SPE2DR26FQHV0 competed?
The extent of competition for SPE2DR26FQHV0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award